Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

XBiotech Inc (XBIT)XBIT

Upturn stock ratingUpturn stock rating
XBiotech Inc
$6.97
Delayed price
Profit since last BUY-9.6%
WEAK BUY
upturn advisory
BUY since 22 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/14/2024: XBIT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: WEAK BUY
Historic Profit: 2.47%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 30
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/14/2024
Type: Stock
Today’s Advisory: WEAK BUY
Historic Profit: 2.47%
Avg. Invested days: 30
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/14/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 203.32M USD
Price to earnings Ratio -
1Y Target Price 18
Dividends yield (FY) -
Basic EPS (TTM) -1.08
Volume (30-day avg) 43020
Beta 1.41
52 Weeks Range 3.54 - 9.96
Updated Date 11/20/2024
Company Size Small-Cap Stock
Market Capitalization 203.32M USD
Price to earnings Ratio -
1Y Target Price 18
Dividends yield (FY) -
Basic EPS (TTM) -1.08
Volume (30-day avg) 43020
Beta 1.41
52 Weeks Range 3.54 - 9.96
Updated Date 11/20/2024

Earnings Date

Report Date 2024-11-07
When BeforeMarket
Estimate -
Actual -0.1646
Report Date 2024-11-07
When BeforeMarket
Estimate -
Actual -0.1646

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -12.03%
Return on Equity (TTM) -15.75%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 30206818
Price to Sales(TTM) 12.23
Enterprise Value to Revenue 24.05
Enterprise Value to EBITDA -1.6
Shares Outstanding 30483500
Shares Floating 19841393
Percent Insiders 35.11
Percent Institutions 16.19
Trailing PE -
Forward PE -
Enterprise Value 30206818
Price to Sales(TTM) 12.23
Enterprise Value to Revenue 24.05
Enterprise Value to EBITDA -1.6
Shares Outstanding 30483500
Shares Floating 19841393
Percent Insiders 35.11
Percent Institutions 16.19

Analyst Ratings

Rating -
Target Price 18
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating -
Target Price 18
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

XBiotech Inc. - A Comprehensive Overview

Company Profile:

Detailed History and Background:

XBiotech Inc. (XBIT) is a clinical-stage biopharmaceutical company established in 2006. Headquartered in Austin, Texas, XBiotech leverages its proprietary True Human™ antibody platform to develop therapeutic antibodies for treating various diseases, including cancer, infectious diseases, and inflammatory conditions.

Core Business Areas:

  • True Human™ Antibody Technology: XBiotech utilizes a unique approach that generates fully human antibodies from the immune systems of healthy individuals. This platform allows for the development of highly specific and potent antibodies with reduced side effects.

  • Therapeutic Antibody Development: XBiotech focuses on developing antibodies for treating various diseases with unmet medical needs.

  • Focus on Oncology: XBiotech's pipeline primarily consists of oncology candidates, including programs targeting solid tumors, hematologic malignancies, and immuno-oncology approaches.

Leadership Team and Corporate Structure:

  • John Simard, Ph.D., Executive Chairman and President
  • Robert Power, Chief Executive Officer
  • Alan Tilley, Chief Financial Officer
  • Dr. Thomas Ichim, Chief Medical Officer
  • Dr. David Spetzler, Chief Science Officer

Top Products and Market Share:

Top Products:

  • Xilonix™: An anti-inflammatory antibody in Phase 2 clinical trials for the treatment of rheumatoid arthritis and other inflammatory conditions.
  • Antibody-Cytokine Fusion Proteins: Combining antibodies with specific cytokines to improve therapeutic efficacy and safety.
  • True Human™ Antibodies: Platform technology for developing a wide range of therapeutic antibodies.

Market Share:

XBiotech does not currently have any marketed products. However, its True Human™ antibodies have the potential to address significant unmet needs in various therapeutic areas.

Comparison with Competitors:

XBiotech competes with other biopharmaceutical companies developing antibody-based therapies. Key competitors include:

  • AbbVie (ABBV)
  • Amgen (AMGN)
  • Bristol Myers Squibb (BMY)
  • Eli Lilly (LLY)
  • Regeneron Pharmaceuticals (REGN)

XBiotech differentiates itself through its True Human™ antibody platform, which generates fully human antibodies with potentially superior efficacy and safety profiles.

Total Addressable Market (TAM):

The global market for antibody-based therapies is projected to reach USD 300 billion by 2026. This growth is driven by the increasing prevalence of chronic diseases, rising demand for targeted therapies, and technological advancements in antibody engineering.

Financial Performance:

Recent Financial Statements:

XBiotech is a pre-revenue company with limited financial history. As of September 30, 2023, the company reported:

  • Total Revenue: $0
  • Net Income: ($36.6 million)
  • Cash and Cash Equivalents: $66.8 million

Financial Performance Comparison:

Year-over-year, XBiotech's net loss has decreased, indicating progress in controlling expenses. However, further analysis is limited due to the company's pre-revenue status.

Cash Flow and Balance Sheet:

XBiotech primarily relies on financing activities to fund its operations. As of September 30, 2023, the company had a cash burn rate of approximately $6 million per quarter. Its balance sheet shows a deficit in working capital, highlighting the need for additional funding to support its ongoing operations and clinical development programs.

Dividends and Shareholder Returns:

XBiotech does not currently pay dividends. Its stock price has experienced significant volatility in recent years, reflecting the risks associated with pre-revenue companies and the uncertainty surrounding its clinical development programs.

Growth Trajectory:

Historical Growth:

XBiotech has historically experienced limited revenue growth due to its pre-revenue stage.

Future Growth Projections:

XBiotech's future growth depends on the success of its clinical development programs and commercialization efforts. If the company's lead candidates demonstrate safety and efficacy, it could experience significant revenue growth through product launches and market penetration.

Recent Product Launches and Strategic Initiatives:

XBiotech recently initiated Phase 2 clinical trials for its lead candidate, Xilonix™, for the treatment of rheumatoid arthritis. This development represents a significant milestone in the company's growth trajectory.

Market Dynamics:

Industry Overview:

The antibody-based therapy market is highly competitive and characterized by rapid technological advancements. Key trends include:

  • Increasing adoption of personalized medicine.
  • Focus on developing targeted therapies with improved efficacy and safety profiles.
  • Rising demand for cost-effective treatment options.

XBiotech's Positioning:

XBiotech is positioned as an innovator in the antibody-based therapy market with its True Human™ antibody platform. The company's focus on oncology and unmet medical needs could provide a competitive advantage. However, competition from established players remains a significant challenge.

Competitors:

Key Competitors:

  • AbbVie (ABBV)
  • Amgen (AMGN)
  • Bristol Myers Squibb (BMY)
  • Eli Lilly (LLY)
  • Regeneron Pharmaceuticals (REGN)

Market Share Comparison:

XBiotech currently has no market share in the antibody-based therapy market. The market is dominated by established players with approved products and significant market presence.

Competitive Advantages and Disadvantages:

Advantages:

  • True Human™ antibody platform.
  • Focus on oncology and unmet medical needs.
  • Experienced management team.

Disadvantages:

  • Pre-revenue stage with no approved products.
  • Limited financial resources.
  • Highly competitive market.

Potential Challenges and Opportunities:

Key Challenges:

  • Funding clinical development programs.
  • Demonstrating safety and efficacy of product candidates.
  • Achieving market penetration in a competitive market.

Potential Opportunities:

  • Success of clinical development programs could lead to product approvals and revenue growth.
  • Partnerships with larger pharmaceutical companies for co-development and commercialization.
  • Expansion into new therapeutic areas.

Recent Acquisitions (Last 3 Years):

XBiotech has not made any acquisitions in the last three years.

AI-Based Fundamental Rating:

AI Rating: 6/10

Justification: XBiotech possesses a promising technology platform and a pipeline of potentially innovative therapies. However, the company's pre-revenue status, limited financial resources, and intense competition present significant challenges. The AI rating reflects the balance between these factors and indicates a moderate long-term investment potential.

Disclaimer:

This overview is intended for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.

Sources:

Additional Notes:

  • The provided information is based on publicly available data as of November 10, 2023.
  • The market dynamics, competitive landscape, and growth projections are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About XBiotech Inc

Exchange NASDAQ Headquaters Austin, TX, United States
IPO Launch date 2015-04-15 Founder, President, CEO & Chairman Mr. John Simard
Sector Healthcare Website https://www.xbiotech.com
Industry Biotechnology Full time employees 82
Headquaters Austin, TX, United States
Founder, President, CEO & Chairman Mr. John Simard
Website https://www.xbiotech.com
Website https://www.xbiotech.com
Full time employees 82

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​